VTVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
vTv Therapeutics Inc (VTVT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, promising catalysts in its pipeline, and technical indicators showing bullish momentum. Despite weak financial performance, the potential for its breakthrough therapy in Type 1 diabetes provides a compelling long-term growth opportunity.
The MACD histogram is positive at 0.521 and expanding, indicating bullish momentum. The RSI_6 is at 63.365, in the neutral zone but leaning towards overbought territory. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the current pre-market price of $39.33 is above the pivot level of $36.779, nearing resistance at R1: $40.475.
Cadisegliatin holds Breakthrough Therapy Designation for Type 1 diabetes and is positioned to be the first approved oral adjunct for this condition.
Analysts have raised price targets significantly, with the highest target at $67, indicating strong confidence in the company's future.
FDA's prioritization of Type 1 diabetes treatments adds regulatory tailwinds.
Bullish technical indicators suggest short-term upward momentum.
Financial performance remains weak, with no revenue and a net income of -$8.7M in Q3
Gross margin dropped to 0%, reflecting operational inefficiencies.
No recent news or significant insider/hedge fund activity to support immediate momentum.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved by 81.85% YoY to -$8.7M, and EPS increased by 22.73% YoY to -1.08. However, gross margin dropped to 0%, indicating no profitability.
Analysts are overwhelmingly bullish, with multiple Buy ratings and price targets ranging from $47 to $67. Analysts highlight the potential of cadisegliatin to address unmet needs in Type 1 diabetes, with peak sales modeled at $2.15B by 2037.
